Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh

被引:124
|
作者
Qadri, Firdausi [1 ]
Wierzba, Thomas F. [3 ]
Ali, Mohammad [3 ,4 ]
Chowdhury, Fahima [1 ]
Khan, Ashraful I. [1 ]
Saha, Amit [1 ]
Khan, Iqbal A. [2 ]
Asaduzzaman, Muhammad [1 ]
Akter, Afroza [1 ]
Khan, Arifuzzaman [1 ]
Begum, Yasmin A. [1 ]
Bhuiyan, Taufiqur R. [1 ]
Khanam, Farhana [1 ]
Chowdhury, Mohiul I. [1 ]
Islam, Taufiqul [1 ]
Chowdhury, Atique I. [1 ]
Rahman, Anisur [1 ]
Siddique, Shah A. [1 ]
Chowdhury, Atique I. [1 ]
Rahman, Anisur [1 ]
Siddique, Shah A. [1 ]
You, Young A. [3 ]
Kim, Deok R. [3 ]
Siddik, Ashraf U. [1 ]
Saha, Nirod C. [1 ]
Kabir, Alamgir [1 ]
Cravioto, Alejandro [3 ]
Desai, Sachin N. [3 ]
Singh, Ajit P. [3 ]
Clemens, John D. [1 ,5 ]
机构
[1] Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh
[2] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh
[3] Int Vaccine Inst, Seoul, South Korea
[4] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA
[5] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 374卷 / 18期
关键词
O1; DHAKA;
D O I
10.1056/NEJMoa1510330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND A single-dose regimen of the current killed oral cholera vaccines that have been prequalified by the World Health Organization would make them more attractive for use against endemic and epidemic cholera. We conducted an efficacy trial of a single dose of the killed oral cholera vaccine Shanchol, which is currently given in a two-dose schedule, in an urban area in which cholera is highly endemic. METHODS Nonpregnant residents of Dhaka, Bangladesh, who were 1 year of age or older were randomly assigned to receive a single dose of oral cholera vaccine or oral placebo. The primary outcome was vaccine protective efficacy against culture-confirmed cholera occurring 7 to 180 days after dosing. Prespecified secondary outcomes included protective efficacy against severely dehydrating culture-confirmed cholera during the same interval, against cholera and severe cholera occurring 7 to 90 versus 91 to 180 days after dosing, and against cholera and severe cholera according to age at baseline. RESULTS A total of 101 episodes of cholera, 37 associated with severe dehydration, were detected among the 204,700 persons who received one dose of vaccine or placebo. The vaccine protective efficacy was 40% (95% confidence interval [CI], 11 to 60%; 0.37 cases per 1000 vaccine recipients vs. 0.62 cases per 1000 placebo recipients) against all cholera episodes, 63% (95% CI, 24 to 82%; 0.10 vs. 0.26 cases per 1000 recipients) against severely dehydrating cholera episodes, and 63% (95% CI, -39 to 90%), 56% (95% CI, 16 to 77%), and 16% (95% CI, -49% to 53%) against all cholera episodes among persons vaccinated at the age of 5 to 14 years, 15 or more years, and 1 to 4 years, respectively, although the differences according to age were not significant (P = 0.25). Adverse events occurred at similar frequencies in the two groups. CONCLUSIONS A single dose of the oral cholera vaccine was efficacious in older children (= 5 years of age) and in adults in a setting with a high level of cholera endemicity.
引用
收藏
页码:1723 / 1732
页数:10
相关论文
共 50 条
  • [41] SINGLE-DOSE KINETICS OF ORAL PRAZEPAM
    ALLEN, MD
    GREENBLATT, DJ
    SHADER, RI
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1979, 25 (02) : 211 - 212
  • [42] Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding
    Ahmed, Tanvir
    Svennerholm, Ann-Mari
    Al Tarique, Abdullah
    Sultana, Gazi N. N.
    Qadri, Firdausi
    VACCINE, 2009, 27 (09) : 1433 - 1439
  • [43] A single-dose antihelminthic treatment does not influence immunogenicity of a meningococcal and a cholera vaccine in Gabonese school children
    Brueckner, Sina
    Agnandji, Selidji Todagbe
    Elias, Johannes
    Berberich, Stefan
    Bache, Emmanuel
    Fernandes, Jose
    Loembe, Marguerite Massinga
    Hass, Johanna
    Lell, Bertrand
    Mordmueller, Benjamin
    Adegnika, Ayola Akim
    Kremsner, Peter
    Esen, Meral
    VACCINE, 2016, 34 (44) : 5384 - 5390
  • [44] SINGLE-DOSE AMPICILLIN THERAPY FOR SEVERE SHIGELLOSIS IN BANGLADESH
    GILMAN, RH
    SPIRA, W
    RABBANI, H
    AHMED, W
    ISLAM, A
    RAHAMAN, MM
    JOURNAL OF INFECTIOUS DISEASES, 1981, 143 (02): : 164 - 169
  • [45] LONG-TERM EFFICACY OF SINGLE-DOSE ORAL TREATMENT IN SCHISTOSOMIASIS HEMATOBIUM
    PUGH, RNN
    TEESDALE, CH
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1984, 78 (01) : 55 - 59
  • [46] Single-dose ebola vaccine sows promise
    Fox, S
    INFECTIONS IN MEDICINE, 2003, 20 (09) : 409 - 409
  • [47] Egg Allergy: Single-Dose Influenza Vaccine
    不详
    ALLERGO JOURNAL, 2011, 20 (04) : 180 - 180
  • [48] Efficacy of single-dose oral ivermectin in treatment of rosacea in relation to demodex mites
    Sharara, Manal A.
    Hamid, Kariman S. Abdel
    Imam, Adel A.
    EGYPTIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2024, 44 (03): : 192 - 199
  • [49] A Single-Dose Intranasal Combination Panebolavirus Vaccine
    Malherbe, Delphine C.
    Kimble, J. Brian
    Atyeo, Caroline
    Fischinger, Stephanie
    Meyer, Michelle
    Cody, S. Gabrielle
    Hyde, Matthew
    Alter, Galit
    Bukreyev, Alexander
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 : S648 - S659
  • [50] SINGLE-DOSE PHARMACOKINETICS AND DOSE PROPORTIONALITY OF ORAL CIBENZOLINE
    KHOO, KC
    SZUNA, AJ
    COLBURN, WA
    AOGAICHI, K
    MORGANROTH, J
    BRAZZELL, RK
    JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 24 (07): : 283 - 288